Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors

Oncogene

Volumn 26, Issue 31, 2007, Pages 4550-4562

  Leupold, J H ^a   Yang, H S ^b   Colburn, N H ^b   Asangani, I ^a   Post, S ^c   Allgayer, H ^a,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Intravasation; Invasion; Pdcd4; Sp1; Sp3; u PAR

Indexed keywords

CHLORAMPHENICOL ACETYLTRANSFERASE; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SP; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TUMOR SUPPRESSOR PROTEIN; UROKINASE RECEPTOR;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL LINE; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION;

APOPTOSIS REGULATORY PROTEINS; BINDING SITES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RECEPTORS, CELL SURFACE; RNA-BINDING PROTEINS; SP TRANSCRIPTION FACTORS; SP1 TRANSCRIPTION FACTOR; SP3 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 34447270490     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210234     Document Type: Article

References (61)

1. Aguirre-Ghiso J, Liu D, Mignatti A, Kovalski K, Ossowski L. (2001). Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 12: 863-879.
2. Aguirre-Ghiso J, Estrada Y, Liu D, Ossowski L. (2003). ERKMAPK activity as a determinant of tumor growth and dormancy; regulation by p38SAPK. Cancer Res 63: 1684-1695.
3. Ahmed N, Oliva K, Wang Y, Quinn M, Rice G. (2003). Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-b1 integrin complex in colon cancer cells. Br J Cancer 89: 374-384.
4. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM et al. (1987). A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47: 3239-3245.
5. Allgayer H, Wang H, Gallick GE, Crabtree A, Mazar A, Jones T et al. (1999a). Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1. J Biol Chem 274: 18428-18437.
6. Allgayer H, Wang H, Shirasawa S, Sasazuki T, Boyd D. (1999b). Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis. Br J Cancer 80: 1884-1891.
7. Allgayer H, Wang H, Wang Y, Heiss MM, Bauer R, Nyormoi O et al. (1999c). Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator protein-2alpha- related factor. J Biol Chem 274: 4702-4714.
8. Azzoni L, Zatsepina O, Abebe B, Bennett IM, Kanakaraj P, Perussia B. (1998). Differential transcriptional regulation of CD161 and a novel gene, 197/15a, by IL-2, IL-15, and IL-12 in NK and T Cells. J Immunol 161: 243-253.
9. Bitomsky N, Bohm M, Klempnauer KH. (2004). Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun. Oncogene 23: 7484-7493.
10. Blasi F. (1993). Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. BioEssays 15: 105-111.
11. Boyd D, Brattain M. (1989). Determination of the effects of epidermal growth factor on urokinase secretion and urokinase receptor display in a well-differentiated human colon carcinoma cell line. Cancer Res 49: 1948-1953.
12. Boyd D, Florent G, Kim P, Brattain M. (1988). Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res 48: 3112-3116.
13. Chen Y, Knosel T, Kristiansen G, Pietas A, Garber ME, Matsuhashi S et al. (2003). Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis. Pathology 200: 640-646.
14. Cmarik J, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H et al. (1999). Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Proc Natl Acad Sci USA 96: 14037-14042.
15. Dikic I, Batzer A, Blaikie P, Obermeier A, Ullrich A, Schlessinger J et al. (1995). Shc binding to nerve growth factor receptor is mediated by the phosphotyrosine interaction domain. J Biol Chem 270: 15125-15129.
16. Duffy M. (1987). Do proteases play a role in cancer invasion and metastasis? Eur J Cancer Clin Oncol 23: 583-589.
17. Fuchs T, Allgayer H. (2003). Transcriptional regulation of the urokinase receptor (u-PAR)-a central molecule of invasion and metastasis. Biol Chem 384: 755-761.
18. Gallick G, Jessup J. (1992). The biology of colorectal carcinoma. In: Ozols RF, Steele G, Kinsella TJ (eds). Current Problems in Cancer. Mosby Year Book Inc: St Louis, pp 261-328.
19. Ganesh S, Sier C, Heerding MM, Griffioen G, Lamers CB, Verspaget HW. (1994). Urokinase receptor and colorectal cancer survival. Lancet 344: 401-402.
20. Göke R, Gregel C, Göke A, Arnold R, Schmidt H, Lankat-Buttgereit B. (2004). Programmed cell death protein 4 (PDCD4) acts as a tumor suppressor in neuroendocrine tumor cells. Ann NY Acad Sci 1014: 220-222.
21. Hapke S, Gawaz M, Dehne K, Kohler J, Marshall JF, Graeff H et al. (2001). beta(3)A-integrin downregulates the urokinasetype plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. Mol Cell Biol 21: 2118-2132.
22. Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW et al. (1995). Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1: 1035-1039.
23. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U et al. (1996). The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer. Eur J Surg Oncol 22: 74-77.
24. Janicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H et al. (1993). Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208.
25. Jansen AP, Camalier C, Colburn NH. (2005). Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res 65: 6034-6041.
26. Jansen AP, Camalier CE, Stark C, Colburn NH. (2004). Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol Cancer Ther 3: 103-110.
27. Kang M, Ahn HS, Lee JY, Matsuhashi S, Park WY. (2002). Up-regulation of PDCD4 in senescent human diploid fibroblasts. Biochem Biophys Res Commun 293: 617-621.
28. Kim J, Yu W, Kovalski K, Ossowski L. (1998). Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94: 353-362.
29. Lankat-Buttgereit B, Gregel C, Knolle A, Hasilik A, Arnold R, Goke R. (2004). Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II. Mol Cell Endocrinol 214: 149-153.
30. Lengyel E, Wang H, Stepp E, Juarez J, Wang Y, Doe W et al. (1996). Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J Biol Chem 271: 23176-23184.
31. Monte S, Lahousse SA, Carter J, Wands JR. (2002). ATP luminescence-based motility-invasion assay. BioTechniques 33: 98-106.
32. Muehlenweg B, Sperl S, Magdolen V, Schmitt M, Harbeck N. (2001). Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. Expert Opin Biol Ther 1: 683-691.
33. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K et al. (1994). Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54: 2900-2907.
34. Onishi Y, Kizaki H. (1996). Molecular cloning of the genes suppressed in RVC lymphoma cells by topoisomerase inhibitors. Biochem Biophys Res Commun 228: 7-13.
35. Onishi Y, Hashimoto S, Kizaki H. (1998). Cloning of the TIS gene suppressed by topoisomerase inhibitors. Gene 215: 453-459.
36. Ossowski L, Clunie G, Masucci MT, Blasi F. (1991). In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 115: 1107-1112.
37. Ossowski L. (1988). In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 107: 2437-2445.
38. Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM, Pekarsky Y. (2005). Akt Phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Res 65: 11282-11286.
39. Qin H, Sun Y, Benveniste EN. (1999). The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 274: 29130-29137.
40. Ritchie S, Boyd F, Wong J, Bonham K. (2000). Transcription of the human c-Src promoter is dependent on Sp1, a novel pyrimidine binding factor SPy, and can be inhibited by triplex-forming oligonucleotides. J Biol Chem 275: 847-854.
41. Schewe D, Biller T, Maurer G, Asangani IA, Leupold JH, Lengyel E et al. (2005). Combination Analysis of Activator Protein-1 Family Members, Sp1 and an Activator Protein-2A-Related Factor Binding to Different Regions of the Urokinase Receptor Gene in Resected Colorectal Cancers. Clin Cancer Res 11: 8538-8548.
42. Schlichter U, Burk O, Worpenberg S, Klempnauer KH. (2001). The chicken Pdcd4 gene is regulated by v-Myb. Oncogene 20: 669-676.
43. Shetty S, Kumar A, Idell S. (1997). Post transcriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Mol Cell Biol 17: 1075-1083.
44. Shetty S, Muniyappa H, Halady PKS, Idell S. (2004). Post transcriptional regulation of urokinase receptor mRNA: identification of a novel urokinase receptor mRNA binding protein in human mesothelioma cells. Am J Respir Cell Mol Biol 31: 100-106.
45. Shibahara K, Asano M, Ishida Y, Aoki T, Koike T, Honjo T. (1995). Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene 166: 297-301.
46. Soejima H, Miyoshi O, Yoshinaga H, Masaki Z, Ozaki I, Kajiwara S et al. (1999). Assignment of the programmed cell death 4 gene (PDCD4) to human chromosome band 10q24 by in situ hybridization. Cytogenet Cell Genet 87: 113-114.
47. Stalberg P, Lopez-Egido JR, Wang S, Gobl A, Oberg K, Skogseid B. (2001). Differentially expressed cDNAs in PLCbeta3-induced tumor suppression in a human endocrine pancreatic tumor cell line: activation of the human mismatch repair protein 3 gene. Biochem Biophys Res Commun 281: 227-231.
48. Su K, Roos M, Yang X, Han I, Paterson AJ, Kudlow JE. (1999). An N-terminal region of Sp1 targets its proteasome-dependent degradation in vitro. J Biol Chem 274: 15194-15202.
49. Wagner S, Atkinson M, Thanner S, Wagner C, Schmitt M, Wilhelm O et al. (1995). Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. Am J Pathol 147: 183-192.
50. Wang H, Skibber J, Juarez J, Boyd D. (1994). Transcriptional activation of the urokinase receptor gene in invasive colon cancer. Int J Cancer 58: 650-657.
51. Wang Y, Dang J, Wang H, Allgayer H, Murrell GA, Boyd D. (2000). Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. Eur J Biochem 267: 3248-3254.
52. Yang H, Cho M, Zakowicz H, Hegamyer G, Sonenberg N, Colburn NH. (2004). A Novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A. Mol Cell Bio 24: 3894-3906.
53. Yang H, Jansen A, Komar AA, Zheng X, Merrick WC, Costes S et al. (2003a). The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 23: 26-37.
54. Yang H, Jansen A, Nair R, Shibahara K, Verma AK, Cmarik JL et al. (2001a). A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-kB or ODC transactivation. Oncogene 20: 669-676.
55. Yang H, Knies J, Stark C, Colburn NH. (2003b). Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene 22: 3712-3720.
56. Yang H, Matthews C, Clair T, Wang Q, Baker AR, Li CCH et al. (2006). Tumorigenesis suppressor Pdcd4 down-regulates MAP4K1 expression to suppress colon carcinoma cell invasion. Mol Cell Biol 26: 1297-1306.
57. Yang X, Su K, Roos MD, Chang Q, Paterson AJ, Kudlow JE. (2001b). O-linkage of N-acetylglucosamine to Sp1 activation domain inhibits its transcriptional capability. Proc Natl Acad Sci USA 98: 6611-6616.
58. Yoshinaga H, Matsuhashi S, Fujiyama C, Masaki Z. (1999). Novel human PDCD4 (H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti-H731 antibody. Pathol Int 49: 1067-1077.
59. Zakowicz H, Yang H, Stark C, Wlodawer A, Laronde-Leblanc N, Colburn NH. (2005). Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GI. RNA 11: 261-274.
60. Zhang Z, DuBois R. (2001). Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene 20: 4450-4456.
61. Zijlstra A, Mellor R, Panzarella G, Aimes RT, Hooper JD, Marchenko ND et al. (2002). A quantitative analysis of rate-limiting steps in the metastatic cascade using humanspecific real-time polymerase chain reaction. Cancer Res 62: 7083-7092.